Generated by AI
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer immunotherapies and combination medicines. The company is building a portfolio of differentiated small molecules and antibodies designed to target key biological pathways involved in tumor growth and immune response. Its current work centers on oncology programs across several solid tumor areas, including lung, gastrointestinal, kidney, and pancreatic cancers. Arcus Biosciences also develops therapies intended to improve how cancer treatments are combined and used in clinical practice, with an emphasis on novel mechanisms such as immuno-oncology and targeted oncology. Headquartered in Hayward, California, Arcus Biosciences operates as a research-driven company working with collaborators to advance investigational medicines through clinical development and toward potential commercialization.
Website3928 Point Eden Way
Hayward, CA, 94545
United States
The latest articles about RCUS.
Arcus Biosciences kept reporting promising kidney cancer data and a long cash runway, yet long-term holders still saw their capital shrink. For Arcus Biosciences shareholders, the loss from the start of the year was 29.6%, including dividends. If you had been weighing an investment back on 2026-01-01, looking at bullish price targets on one side and concerns about regulatory risk and partner dependence on the other, which signals would have deserved the most attention? A Narrative on Simply...
Summary of Oct 20's posts. Generated by AI.
No summary yet.
Summary of Aug 23's posts. Generated by AI.
Summary of Jan 30's posts. Generated by AI.
Investors talking about RCUS also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.